



24 Disember 2025
24 December 2025
P.U. (A) 460

WARTA KERAJAAN PERSEKUTUAN

*FEDERAL GOVERNMENT
GAZETTE*

PERINTAH RACUN
(PINDAAN SENARAI RACUN) 2025

*POISONS
(AMENDMENT OF POISONS LIST) ORDER 2025*

DISIARKAN OLEH/
PUBLISHED BY
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL'S CHAMBERS

AKTA RACUN 1952

PERINTAH RACUN (PINDAAN SENARAI RACUN) 2025

PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [*Akta 366*], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut:

Nama

1. Perintah ini bolehlah dinamakan **Perintah Racun (Pindaan Senarai Racun) 2025**.

Pindaan Jadual Pertama

2. Akta Racun 1952 dipinda dalam Jadual Pertama—

(a) dalam Senarai Racun—

- (i) dengan memasukkan selepas butiran “Atracurium; its salts” dan butir-butir yang berhubungan dengannya butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	

“Avalglucosidase alfa	-	All preparations”;			
-----------------------	---	--------------------	--	--	--

- (ii) dengan memasukkan selepas butiran “Axitinib” dan butir-butir yang berhubungan dengannya butir dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	

“Azacitidine	-	All preparations”;			
--------------	---	--------------------	--	--	--

- (iii) dengan memasukkan selepas butiran “Bortezomib” dan butir-butir yang berhubungan dengannya butir dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	

“Bosutinib	-	All preparations”;			
------------	---	--------------------	--	--	--

- (iv) dengan memasukkan selepas butiran “Cladribine” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Clascoterone	-	All preparations”;			

- (v) dengan memasukkan selepas butiran “Chlormethiazole; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Chlormethine	-	All preparations”;			

- (vi) dengan memasukkan selepas butiran “Dehydroemetine; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Delamanid	-	All preparations";			

(vii) dengan memasukkan selepas butiran "Escitalopram" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Eslicarbazepine acetate	-	All preparations";			

(viii) dengan memasukkan selepas butiran "Finasteride" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Finerenone	-	All preparations";			

- (ix) dengan memasukkan selepas butiran "Losartan; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Lotilaner	-	All preparations";			

- (x) dengan memasukkan selepas butiran "Miconazole; its salts" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Midodrine hydrochloride	-	"All preparations";			

- (xi) dengan memasukkan selepas butiran "Miglitol" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Milbemycin oxime	-	"All preparations";			

- (xii) dalam senarai "Monoclonal antibody; includes the following:"—

- (A) dengan memasukkan selepas butiran "Emicizumab" butiran "Enfortumab"; dan
- (B) dengan memasukkan selepas butiran "Mepolizumab" butiran "Mosunetuzumab";

- (xiii) dengan memasukkan selepas butiran “Olaquinox” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Olipudase alfa	-	All preparations”;			

- (xiv) dengan memasukkan selepas butiran “Omidenepag” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Onasemnogene abeparvovec	-	All preparations”;			

- (xv) dengan memasukkan selepas butiran “Sodium cromoglycate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Sodium hyaluronate	-	-	All preparations for parenteral administration";	-	-	All preparations unless in Group C";

(xvi) dengan memasukkan selepas butiran "Tegaserod" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
"Tegoprazan	-	All preparations"; dan				

(xvii) dengan memasukkan selepas butiran "Tirofiban" dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
"Tirzepatide	-	All preparations"; dan			

(b) dalam Lampiran kepada Senarai Racun—

- (i) dalam senarai "**Anthelmintics:**", dengan memasukkan selepas butiran "Melarsomine" butiran "Milbemycin oxime";
- (ii) dalam senarai "**Anticonvulsants:**", dengan memasukkan selepas butiran "Carbamazepine" butiran "Eslicarbazepine acetate";
- (iii) dalam senarai "**Antidiabetics:**", dengan memasukkan selepas butiran "Sitagliptin" butiran "Tirzepatide";
- (iv) dalam senarai "**Antineoplastic agents and Immunosuppressants:**"—
 - (A) dengan memasukkan selepas butiran "Axitinib" butiran "Azacitidine";
 - (B) dengan memasukkan selepas butiran "Bortezomib" butiran "Bosutinib";

- (C) dengan memasukkan selepas butiran “Chlorambucil; its salts” butiran “Chlormethine”;
 - (D) dengan memasukkan selepas butiran “Durvalumab” butiran “Enfortumab”; dan
 - (E) dengan memasukkan selepas butiran “Mitoxantrone; its salts” butiran “Mosunetuzumab”;
- (v) dalam senarai “**Antitubercular agents:**”, dengan memasukkan selepas butiran “Bedaquiline” butiran “Delamanid”;
- (vi) dalam senarai “**Anti-ulcer agents:**”, dengan memasukkan selepas butiran “Roxatidine” butiran “Tegoprazan”;
- (vii) dalam senarai “**Diuretics:**”, dengan memasukkan selepas butiran “Ethacrynic acid; its salts” butiran “Finerenone”;
- (viii) dalam senarai “**Sympathomimetic amines:**”, dengan memasukkan selepas butiran “Indanazoline; its salts” butiran “Midodrine hydrochloride”; dan
- (ix) dalam senarai “**Miscellaneous:**”—
- (A) dengan memasukkan selepas butiran “Atosiban” butiran “Avalglucosidase alfa”;

- (B) dengan memasukkan selepas butiran “Citicoline” butiran “Clascoterone”;
- (C) dengan memasukkan selepas butiran “Lonoctocog alfa” butiran “Lotilaner”;
- (D) dengan memasukkan selepas butiran “Olaquinox” butiran “Olipudase alfa”;
- (E) dengan memasukkan selepas butiran “Omidenepag” butiran “Onasemnogene abeparvovec”; dan
- (F) dengan memasukkan selepas butiran “Sodium cromoglycate” butiran “Sodium hyaluronate”.

Dibuat 21 November 2025
[KKM.600-18/2/95; PN(PU2)172/JLD.21]

DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD
Menteri Kesihatan

POISONS ACT 1952

POISONS (AMENDMENT OF POISONS LIST) ORDER 2025

IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order:

Citation

1. This order may be cited as the **Poisons (Amendment of Poisons List) Order 2025**.

Amendment of First Schedule

2. The Poisons Act 1952 is amended in the First Schedule —

(a) in the Poisons List—

- (i) by inserting after item “Atracurium; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Avalglucosidase alfa	-	All preparations”;					

- (ii) by inserting after item “Axitinib” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Azacitidine	-	All preparations”;					

- (iii) by inserting after item “Bortezomib” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Bosutinib	-	All preparations”;					

- (iv) by inserting after item “Cladribine” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>	
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>			
“Clascoterone	-	All preparations”;					

- (v) by inserting after item “Chlormethiazole; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Chlormethine	-	All preparations”;				

- (vi) by inserting after item “Dehydroemetine; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Delamanid	-	All preparations”;				

(vii) by inserting after item “Escitalopram” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Eslicarbazepine acetate	-	All preparations”;				

(viii) by inserting after item “Finasteride” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Finerenone	-	All preparations”;				

(ix) by inserting after item “Losartan; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Lotilaner	-	All preparations”;				

(x) by inserting after item “Miconazole; its salts” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Midodrine hydrochloride	-	All preparations”;				

(xi) by inserting after item “Miglitol” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Milbemycin oxime	-	All preparations”;				

(xii) in the list of “Monoclonal antibody; includes the following:” —

(A) by inserting after item “Emicizumab” item “Enfortumab”; and

(B) by inserting after item “Mepolizumab” item “Mosunetuzumab”;

(xiii) by inserting after item “Olaquinox” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Olipudase alfa	-	All preparations”;			

(xiv) by inserting after item “Omidenepag” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Onasemnogene abeparvovec	-	All preparations”;			

(xv) by inserting after item “Sodium cromoglycate” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Sodium hyaluronate	-	-	All preparations for parenteral administration”;	-	-	All preparations unless in Group C”;

(xvi) by inserting after item “Tegaserod” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II</i>	<i>Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>		
“Tegoprazan	-	All preparations”;				

(xvii) by inserting after item “Tirofiban” and the particulars relating to it the following item and particulars:

<i>Names</i>	<i>Part I</i>				<i>Part II Exempt</i>
	<i>Group A</i>	<i>Group B</i>	<i>Group C</i>	<i>Group D</i>	
“Tirzepatide	-	All preparations”; and			

(b) in the Appendix to the Poisons List—

- (i) in the list of “**Anthelmintics:**”, by inserting after item “Melarsomine” item “Milbemyacin oxime”;
- (ii) in the list of “**Anticonvulsants:**”, by inserting after item “Carbamazepine” item “Eslicarbazepine acetate”;
- (iii) in the list of “**Antidiabetics:**”, by inserting after item “Sitagliptin” item “Tirzepatide”;
- (iv) in the list of “**Antineoplastic agents and Immunosuppressants:**”—
 - (A) by inserting after item “Axitinib” item “Azacitidine”;
 - (B) by inserting after item “Bortezomib” item “Bosutinib”;

- (C) by inserting after item “Chlorambucil; its salts” item “Chlormethine”;
- (D) by inserting after item “Durvalumab” item “Enfortumab”; and
- (E) by inserting after item “Mitoxantrone; its salts” item “Mosunetuzumab”;
- (v) in the list of “**Antitubercular agents:**”, by inserting after item “Bedaquiline” item “Delamanid”;
- (vi) in the list of “**Anti-ulcer agents:**”, by inserting after item “Roxatidine” item “Tegoprazan”;
- (vii) in the list of “**Diuretics:**”, by inserting after item “Ethacrynic acid; its salts” item “Finerenone”;
- (viii) in the list of “**Sympathomimetic amines:**”, by inserting after item “Indanazoline; its salts” item “Midodrine hydrochloride”; and
- (ix) in the list of “**Miscellaneous:**” —
 - (A) by inserting after item “Atosiban” item “Avalglucosidase alfa”;
 - (B) by inserting after item “Citicoline” item “Clascoterone”;

- (C) by inserting after item “Lonoctocog alfa” item “Lotilaner”;
- (D) by inserting after item “Olaquinox” item “Olipudase alfa”;
- (E) by inserting after item “Omidenepag” item “Onasemnogene abeparvovec”; and
- (F) by inserting after item “Sodium cromoglycate” item “Sodium hyaluronate”.

Made 21 November 2025
[KKM.600-18/2/95; PN(PU2)172/JLD.21]

DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD
Minister of Health